HE4 的表达与乳腺癌的淋巴结转移和无病生存期相关。
HE4 expression can be associated with lymph node metastases and disease-free survival in breast cancer.
机构信息
Department of Surgery II, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama, Yufu, Oita, 879-5593, Japan.
出版信息
Anticancer Res. 2010 Nov;30(11):4779-83.
BACKGROUND
This study investigated the potential of HE4 to predict disease-free survival for patients with breast cancer.
PATIENTS AND METHODS
One hundred and twenty-nine patients with breast cancer underwent surgery from January 2004 to September 2009. Immunohistochemical analysis (IHC) and RT-PCR were used to determine the expression of HE4 which was compared with the clinicopathological factors or prognosis.
RESULTS
A total of 71 of 129 cases (55%) were HE4 positive and two cell lines expressed HE4 protein and mRNA. No correlation was found between HE4 expression by IHC and clinicopathological factors; however, lymph node involvement was closely associated with HE4 expression. Five-year disease-free survival in the HE4-positive group (58.6%) was significantly worse than that in the negative group (85.6%, p=0.04).
CONCLUSION
These data showed that HE4 expression is associated with lymph node involvement and is a possible predictive factor of breast cancer recurrence.
背景
本研究旨在探讨 HE4 对预测乳腺癌患者无病生存的潜在价值。
患者与方法
本研究纳入了 129 例于 2004 年 1 月至 2009 年 9 月间接受手术治疗的乳腺癌患者。采用免疫组化分析（IHC）和 RT-PCR 来确定 HE4 的表达情况，并将其与临床病理因素或预后进行比较。
结果
在 129 例患者中，有 71 例（55%）为 HE4 阳性，两种细胞系均表达 HE4 蛋白和 mRNA。IHC 检测到的 HE4 表达与临床病理因素之间无相关性，但淋巴结受累与 HE4 表达密切相关。HE4 阳性组的 5 年无病生存率（58.6%）明显低于阴性组（85.6%，p=0.04）。
结论
这些数据表明，HE4 的表达与淋巴结受累有关，可能是乳腺癌复发的一个预测因素。
Zotero 插件